Meet the One Million Strong – Barbara B. From Oregon

Meet Barbara Barbara Baughman, caregiver Hillsboro, Oregon Barbara’s Story This is my husband Rodger, who was diagnosed in February 2008 with stage IV colorectal cancer. We were at our beach house when Rodger began experiencing major bleeding. He decided that he wanted to be back…

Read Full Post

Personalizing Personalized Medicine

On Monday, April 25th, Fight Colorectal Cancer held a free patient webinar that tackled the somewhat complex but fascinating topic of personalized medicine. Personalized medicine is what the cancer community calls treatments that are tailored to each patient’s genetic makeup. It is the future of…

Read Full Post

Leading GI Cancer Researcher Updates Patients

Last night, Dr. Edith Mitchell of Thomas Jefferson University Kimmel Cancer Center in Philadelphia, PA, updated colorectal cancer patients on the latest research and treatment news in an online webinar. Dr. Mitchell highlighted the most important news for colon and rectal cancer patients to come…

Read Full Post

No Benefit Adding Cetuximab to Chemo for Stage III Colon Cancer

Adding Erbitux® (cetuximab) to standard chemotherapy for stage III colon cancer didn’t improve patient outcomes and added more side effects. All of the patients in the NO147 trial had cancer that had spread to their lymph nodes and had surgery before beginning chemotherapy. They had…

Read Full Post

Erbitux Plus Chemo Can Make Liver Mets Surgery Possible

Chemotherapy and Erbitux® (cetuximab) reduced liver tumors from colorectal cancer enough for patients to have them removed surgically. Although their cancer was initially too extensive to be surgically removed (resected) chemotherapy combined with Erbitux allowed about a third of patients to have surgery that completely…

Read Full Post

Stage III Cetuximab Trial Closed

It doesn’t help patients to add Erbitux to FOLFOX chemotherapy after surgery for stage III colon cancer a data monitoring committee for a clinical trial testing the new treatment has decided. Because the analysis showed that patients were not benefiting from adding Erbitux to FOLFOX…

Read Full Post

Colorectal Cancer News in Brief: October 2

Briefly: More colorectal cancer patients experience severe rash from Erbitux than other cancer patients, and significantly more men and younger people have severe rash than women and patients over 70. Where you live in the United States makes a big difference in your risk of…

Read Full Post

Early Tumor Shrinkage Points to Good Erbitux Outcomes

Patients with advanced colorectal cancer whose tumors have gotten smaller six weeks after starting treatment with Erbitux had a much longer time before their cancer got worse and almost twice the overall survival as patients whose tumors didn’t shrink. Patients in the BOND study had…

Read Full Post